Trial Profile
An Exploratory, Proof-of-Concept Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2023
Price :
$35
*
At a glance
- Drugs Fostamatinib (Primary)
- Indications Hidradenitis suppurativa
- Focus Pharmacodynamics; Proof of concept
- 10 Jun 2023 Results assessing the safety, tolerability and clinical response at week 4 and week 12 of fostamatinib , published in the Journal of the American Academy of Dermatology.
- 27 Feb 2023 Status changed from recruiting to completed.
- 11 Apr 2022 New trial record